Warning: The NCBI web site requires JavaScript to function. more...
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J, Pornon A, Chen B, Chen S, Evans DB.
Breast Cancer Res. 2008;10(4):R56. Epub 2008 Jul 8.
Related citations
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.
Clin Cancer Res. 2005 Jul 15;11(14):5319-28.
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.
Clin Cancer Res. 2005 Feb 15;11(4):1563-71.
Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
Piao W, Wang Y, Adachi Y, Yamamoto H, Li R, Imsumran A, Li H, Maehata T, Ii M, Arimura Y, Lee CT, Shinomura Y, Carbone DP, Imai K.
Mol Cancer Ther. 2008 Jun;7(6):1483-93.
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, Petronini PG.
Breast Cancer Res Treat. 2010 Nov;124(1):79-88. Epub 2010 Jan 7.
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I, Itoh T, Chen S.
J Steroid Biochem Mol Biol. 2005 Dec;97(4):360-8. Epub 2005 Nov 2.
Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition.
Guerreiro AS, Boller D, Shalaby T, Grotzer MA, Arcaro A.
Int J Cancer. 2006 Dec 1;119(11):2527-38.
Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H.
Int J Oncol. 2008 Nov;33(5):1107-13.
The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW.
Mol Cancer Ther. 2004 May;3(5):527-35.
Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E.
Cancer Res. 2001 Sep 15;61(18):6747-54.
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A, Brodie AM, Njar VC.
Cancer Res. 2006 Dec 1;66(23):11485-93.
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ, Jelovac D, Thiantanawat A, Brodie AM.
Clin Cancer Res. 2002 Jul;8(7):2378-88.
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
Acta Oncol. 2009;48(4):522-31.
Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.
Clin Cancer Res. 2006 Nov 15;12(22):6772-80.
Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.
Doepfner KT, Spertini O, Arcaro A.
Leukemia. 2007 Sep;21(9):1921-30. Epub 2007 Jun 21.
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, Jänne PA, Saijo N, Minami H.
Cancer Lett. 2009 Sep 8;282(1):14-24. Epub 2009 Apr 3.
Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN.
Gynecol Oncol. 2006 Feb;100(2):389-96. Epub 2005 Nov 21.
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA, Lebwohl D.
Semin Oncol. 2006 Apr;33(2 Suppl 7):S18-25. Review.
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A.
Ann Oncol. 2008 Nov;19(11):1860-9. Epub 2008 Jul 17.
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.
Cancer Res. 2005 Jun 15;65(12):5439-44.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on